Hidradenitis suppurativa (HS) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051119
HS restriction and item codes
Do not release this attachment externally. See Freedom of Information - Information Publication Scheme.
PBS HS restriction and item codes
FAQs from Service Officers
Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.
Item |
Description |
1 |
How many failures are allowed in one treatment cycle for PBS-subsidised treatment of hidradenitis suppurativa (HS)? Three. There are only two biological medicines PBS listed to treat HS. Patients can fail one biological medicine twice within the same treatment cycle. |
2 |
How many prescriptions or details of the proposed prescriptions are required for the initial/change/recommencement of treatment with adalimumab? Two. They are for:
|
3 |
How many prescriptions or details of the proposed prescriptions are required for the initial/change/recommencement of treatment with secukinumab? When there is:
Note: see HS code sheet for the correct item code(s), quantity and repeats to be entered in the OPA system. |
4 |
Can increased quantity and/or repeats be authorised for secukinumab? The quantity of secukinumab can be increased from 2 to 4 for all treatment phases (excluding the induction) if the patient is dosed at 300 mg per fortnight. No increase in the maximum number of listed repeats can be authorised. Note: see HS code sheet for details. |
5 |
Can the dynamic Q+A in relation to timeframe be answered in OPA when the wording is different on the PBS application form? Yes. Providing the box has been ticked on the application form, any question in relation to timeframe can be answered correctly in OPA. |